Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Informing Endpoints for Clinical Trials of Geographic Atrophy

15 Sept 2024

Abstract excerpt

Geographic atrophy (GA), the non-neovascular advanced form of age-related macular degeneration, remains an important disease area in which treatment needs are currently unmet. Recent clinical trials using drugs that target the complement pathway have shown modest yet consistent reductions in GA expansion but without commensurate changes in measures of visual function. In this review, we summarize information from...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Retinal Development and Disorders
Share to Retinal Diseases and Treatments
Share to Retinal Imaging and Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39292553
DOI: 10.1146/annurev-vision-101922-045110

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Informing Endpoints for Clinical Trials of Geographic AtrophyPMID 39292553Read ↗

The roadmap to geographic atrophy treatment: A journey of trials and promiseSemantic proximity Read ↗

Local Complement Inhibition for Geographic Atrophy in Age-Related Macular Degeneration: Prospects, Challenges, and Unanswered QuestionsSemantic proximity Read ↗

Treating patients with geographic atrophy: are we there yet?Semantic proximity Read ↗

Geographic atrophy: where we are now and where we are goingSemantic proximity Read ↗

COMPLEMENT INHIBITION FOR GEOGRAPHIC ATROPHYSemantic proximity Read ↗

Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE study.Semantic proximity Read ↗

Incidence and progression of geographic atrophy: observations from a population-based cohort.Semantic proximity Read ↗

Investigating Macular Tissue Integrity Index as a Novel Biomarker in Geographic AtrophySemantic proximity Read ↗

Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular DegenerationSemantic proximity Read ↗

Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials.Semantic proximity Read ↗

Complement system modulation in age-related macular degeneration: navigating failures, building future successesSemantic proximity Read ↗

Real-World Outcomes with Complement Inhibitors for Geographic Atrophy: A Comparative Study of Pegacetacoplan versus Avacincaptad PegolSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.